Literature DB >> 6233053

Clinical use of immunoglobulins.

D B McClelland, P L Yap.   

Abstract

The use of immunoglobulins for prophylaxis and therapy are reviewed. Normal and hyperimmune immunoglobulins have well established clinical applications. These are summarized in Table 14. This form of therapy has now entered a period of rapid change due to the availability of human immunoglobulins which are safe for intravenous use, permitting large doses to be given rapidly. This will permit reappraisal of many conventional applications and exploration of new possibilities for the use of these products. The approaching wide availability of monoclonal antibodies for clinical use will open up a further wide range of new therapeutic applications, providing that concerns over the products' safety are allayed .

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233053

Source DB:  PubMed          Journal:  Clin Haematol        ISSN: 0308-2261


  4 in total

1.  Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia.

Authors:  T Sumer; A Abumelha; I al-Mulhim; M al-Fadil
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

2.  Immune phagocytosis inhibition by commercial immunoglobulins.

Authors:  J Neppert; M Clemens; C Mueller-Eckhardt
Journal:  Blut       Date:  1986-02

3.  Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies.

Authors:  G R Barclay; B B Scott
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

4.  Cross-reactive Antibodies against avian influenza virus A (H5N1).

Authors:  Sathit Pichyangkul; Anan Jongkaewwattana; Arunee Thitithanyanont; Peeraya Ekchariyawat; Suwimon Wiboon-ut; Amporn Limsalakpetch; Kosol Yongvanitchit; Utaiwan Kum-Arb; Rangsini Mahanonda; Pongsak Utaisincharoen; Stitaya Sirisinha; Carl J Mason; Mark M Fukuda
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.